Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Elastic Meta-Analytic-predictive Prior for Dynamically Borrowing Information from Historical Data with Application to Biosimilar Clinical Trials.

A Bayesian Adaptive Design for Biosimilar Trials with Time-to-event Endpoint.

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Power prior for borrowing the real-world data in bioequivalence test with a parallel design

Bayesian Approach for Design and Analysis of Medical Device Trials in the Era of Modern Clinical Studies

Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

A Bayesian Hybrid Design with Borrowing from Historical Study

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

Adaptive seamless design for establishing pharmacokinetics and efficacy equivalence in developing biosimilars

Incorporating Historical Information to Improve Phase I Clinical Trials

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Optimizing Interim Analysis Timing for Bayesian Adaptive Commensurate Designs

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

An Adaptive Three‐Arm Comparative Clinical Endpoint Bioequivalence Study Design With Unblinded Sample Size Re‐Estimation and Optimized Allocation Ratio

BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS

Bayesian design of clinical trials using the scale transformed power prior